IN2013MU01985A - - Google Patents

Download PDF

Info

Publication number
IN2013MU01985A
IN2013MU01985A IN1985MU2013A IN2013MU01985A IN 2013MU01985 A IN2013MU01985 A IN 2013MU01985A IN 1985MU2013 A IN1985MU2013 A IN 1985MU2013A IN 2013MU01985 A IN2013MU01985 A IN 2013MU01985A
Authority
IN
India
Prior art keywords
empagliflozin
amorphous form
preparation
provides
abstarct
Prior art date
Application number
Inventor
Shriprakash Dhar Dwivedi
Brij Khera
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN1985MU2013 priority Critical patent/IN2013MU01985A/en
Publication of IN2013MU01985A publication Critical patent/IN2013MU01985A/en

Links

Abstract

ABSTARCT AMORPHOUS FORM OF EMPAGLIFLOZIN AND PROCESS FOR PREPARATION THEREOF The invention provides an amorphous form of empagliflozin of formula (I) and a process for the preparation thereof. The invention also provides a pharmaceutical composition comprising an amorphous form of empagliflozin together with one or more of pharmaceutically acceptable carriers, excipients and diluents. (I)
IN1985MU2013 2013-06-10 2013-06-10 IN2013MU01985A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN1985MU2013 IN2013MU01985A (en) 2013-06-10 2013-06-10

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1985MU2013 IN2013MU01985A (en) 2013-06-10 2013-06-10

Publications (1)

Publication Number Publication Date
IN2013MU01985A true IN2013MU01985A (en) 2015-05-29

Family

ID=54396291

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1985MU2013 IN2013MU01985A (en) 2013-06-10 2013-06-10

Country Status (1)

Country Link
IN (1) IN2013MU01985A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016169534A1 (en) * 2015-04-24 2016-10-27 Zentiva, K. S. Solid forms of amorphous empagliflozin
CN106317035A (en) * 2015-06-23 2017-01-11 中美华世通生物医药科技（武汉）有限公司 Empagliflozin monocrystalline and preparation method and purpose thereof
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
US10428053B2 (en) 2015-09-15 2019-10-01 Laurus Labs Limited Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
WO2021123165A1 (en) 2019-12-19 2021-06-24 Krka, D.D., Novo Mesto Dosage form comprising amorphous solid solution of empagliflozin with polymer

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
WO2016169534A1 (en) * 2015-04-24 2016-10-27 Zentiva, K. S. Solid forms of amorphous empagliflozin
CN106317035A (en) * 2015-06-23 2017-01-11 中美华世通生物医药科技（武汉）有限公司 Empagliflozin monocrystalline and preparation method and purpose thereof
US10428053B2 (en) 2015-09-15 2019-10-01 Laurus Labs Limited Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
US10738038B2 (en) 2015-09-15 2020-08-11 Laurus Labs Limited Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
US10836753B2 (en) 2015-09-15 2020-11-17 Laurus Labs Limited Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
US11040961B2 (en) 2015-09-15 2021-06-22 Laurus Labs Limited Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
WO2021123165A1 (en) 2019-12-19 2021-06-24 Krka, D.D., Novo Mesto Dosage form comprising amorphous solid solution of empagliflozin with polymer

Similar Documents

Publication Publication Date Title
MX2016013689A (en) 4-amino-imidazoquinoline compounds.
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
MA39749A (en) Piperidine-dione derivatives
GEP20186933B (en) Substituted dihydroisoquinoline compounds
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
TW201144301A (en) Processes for preparing linezolid
IN2013MU00711A (en)
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
IN2013MU01985A (en)
WO2014153495A3 (en) Novel stat3 inhibitors
NZ742805A (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
IN2013MU03862A (en)
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
GEP20186879B (en) Cycloalkyl-linked diheterocycle derivatives
IN2013MU01111A (en)
MX2015013048A (en) A crystalline form of an anxiolytic compound.
IN2013MU03422A (en)
IN2014MU00859A (en)
IN2013MU03308A (en)
IN2013MU01226A (en)
MX2016002186A (en) Process for preparing dronedarone and salts thereof.
IN2014KN02584A (en)
IN2013MU01160A (en)
IN2013MU02010A (en)